galinpepimut-s

**Galinpepimut-s** is an investigational multivalent heteroclitic peptide cancer vaccine targeting Wilms tumor protein 1. It contains four WT1-derived peptide antigens designed to generate WT1-specific CD4-positive and CD8-positive T-cell responses against WT1-expressing tumor cells. SELLAS Life Sciences is developing galinpepimut-s primarily as maintenance therapy for acute myeloid leukemia after second or later complete remission in the pivotal Phase 3 REGAL trial; the program has also been evaluated in solid tumors and hematologic malignancies, including colorectal cancer, ovarian cancer, triple-negative breast cancer, small-cell lung cancer, malignant pleural mesothelioma, and multiple myeloma. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/galinpepimut-s))

Brand names

galinpepimut-S

Other names

Wilms tumor 1 peptide vaccineWilms tumor gene 1 peptide vaccine